These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23121822)

  • 21. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.
    Anttila L; Kunz M; Marr J
    Contraception; 2009 Nov; 80(5):445-51. PubMed ID: 19835718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Action of hormonal contraceptives on the coagulation system and some of its inhibitors.
    Misz M; Beck P
    Acta Med Hung; 1986; 43(3):301-10. PubMed ID: 2438639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experience with a new low dose oral contraceptive: norgestimate & ethinyl estradiol.
    Rubio-Lotvin B; Gonzales-Ansorena R
    Acta Eur Fertil; 1978 Mar; 9(1):1-6. PubMed ID: 696184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick S; Kaye JA; Li L; Jick H
    Contraception; 2007 Jul; 76(1):4-7. PubMed ID: 17586129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms.
    Brown C; Ling F; Wan J
    J Reprod Med; 2002 Jan; 47(1):14-22. PubMed ID: 11838304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.
    Freeman EW
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():27-34; discussion 42-3. PubMed ID: 12659404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous oral levonorgestrel/ethinyl estradiol for treating premenstrual dysphoric disorder.
    Halbreich U; Freeman EW; Rapkin AJ; Cohen LS; Grubb GS; Bergeron R; Smith L; Mirkin S; Constantine GD
    Contraception; 2012 Jan; 85(1):19-27. PubMed ID: 22067793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hypophyseal reaction state during oral contraceptiva (author's transl)].
    Gitsch E; Schneider WH; Schmid R; Spona J
    Wien Klin Wochenschr; 1981 Oct; 93(19):599-601. PubMed ID: 6798764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations.
    Bäckström T; Hansson-Malmström Y; Lindhe BA; Cavalli-Björkman B; Nordenström S
    Contraception; 1992 Sep; 46(3):253-68. PubMed ID: 1451521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Premenstrual syndrome and oral contraceptives of different character.
    Hetényi G
    Ther Hung; 1988; 36(4):170-3. PubMed ID: 3253960
    [No Abstract]   [Full Text] [Related]  

  • 32. The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris.
    Olson WH; Lippman JS; Robisch DM
    Int J Fertil Womens Med; 1998; 43(6):286-90. PubMed ID: 9920537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of various oral contraceptive combinations on premenstrual symptoms.
    Andersch B
    Int J Gynaecol Obstet; 1982 Dec; 20(6):463-9. PubMed ID: 6130993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
    Kearney BP; Mathias A
    Pharmacotherapy; 2009 Aug; 29(8):924-9. PubMed ID: 19637945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.
    Schwartz JI; Liu F; Wang YH; Pramanik B; Johnson-Levonas AO; Gutierrez MJ; Lai E; Wagner JA
    Am J Ther; 2009; 16(6):487-95. PubMed ID: 19940609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Our 3- to 5-year experience with Anteovin].
    Pŭnevska M; Veltova L; Vlasova D
    Akush Ginekol (Sofiia); 1999; 38(2):54-5. PubMed ID: 10730393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SHBG, testosterone, androstenedione, 17-OH-Progesterone plasma levels in PCO affected women treated with a triphasic oral contraceptive.
    Negri P; Agnello G; Borghesani F; Tomain L; Minisci N; D'Errico G; Cavallini AR
    Acta Eur Fertil; 1987; 18(6):375-80. PubMed ID: 3454501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
    Yonkers KA; Brown C; Pearlstein TB; Foegh M; Sampson-Landers C; Rapkin A
    Obstet Gynecol; 2005 Sep; 106(3):492-501. PubMed ID: 16135578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life.
    Borenstein J; Yu HT; Wade S; Chiou CF; Rapkin A
    J Reprod Med; 2003 Feb; 48(2):79-85. PubMed ID: 12621790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How to determine symptom severity in premenstrual syndrome: a combination of daily symptom ratings and interviews.
    Nyberg S
    Sex Reprod Healthc; 2011 Nov; 2(4):161-8. PubMed ID: 22055985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.